Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

20 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Survival improvements of marine mammals in zoological institutions mirror historical advances in human longevity.
Tidière M, Colchero F, Staerk J, Adkesson MJ, Andersen DH, Bland L, Böye M, Brando S, Clegg I, Cubaynes S, Cutting A, De Man D, Derocher AE, Dorsey C, Elgar W, Gaglione E, Anderson Hansen K, Jungheim A, Kok J, Laule G, Goya AL, Miller L, Monreal-Pawlowsky T, Mucha K, Owen MA, Petersen SD, Pilfold N, Richardson D, Richardson ES, Sabo D, Sato N, Shellabarger W, Skovlund CR, Tomisawa K, Trautwein SE, Bonn WV, Elk CV, Von Fersen L, Wahlberg M, Zhang P, Zhang X, Conde DA. Tidière M, et al. Among authors: gaglione e. Proc Biol Sci. 2023 Oct 25;290(2009):20231895. doi: 10.1098/rspb.2023.1895. Epub 2023 Oct 18. Proc Biol Sci. 2023. PMID: 37848064 Free PMC article.
CD49d Expression Identifies a Biologically Distinct Subtype of Chronic Lymphocytic Leukemia with Inferior Progression-Free Survival on BTK Inhibitor Therapy.
Alsadhan A, Chen J, Gaglione EM, Underbayev C, Tuma PL, Tian X, Freeman LA, Baskar S, Nierman P, Soto S, Itsara A, Ahn IE, Sun C, Bibikova E, Hartmann TN, Mhibik M, Wiestner A. Alsadhan A, et al. Among authors: gaglione em. Clin Cancer Res. 2023 Sep 15;29(18):3612-3621. doi: 10.1158/1078-0432.CCR-22-3217. Clin Cancer Res. 2023. PMID: 37227160 Free PMC article.
Cytotoxicity of the CD3×CD20 bispecific antibody epcoritamab in CLL is increased by concurrent BTK or BCL-2 targeting.
Mhibik M, Gaglione EM, Eik D, Herrick J, Le J, Ahn IE, Chiu C, Wielgos-Bonvallet M, Hiemstra IH, Breij ECW, Chen J, Reilly EB, Epling-Burnette PK, Szafer-Glusman E, Sun C, Wiestner A. Mhibik M, et al. Among authors: gaglione em. Blood Adv. 2023 Aug 8;7(15):4089-4101. doi: 10.1182/bloodadvances.2022009517. Blood Adv. 2023. PMID: 37219524 Free PMC article.
Patient-derived Siglec-6-targeting antibodies engineered for T-cell recruitment have potential therapeutic utility in chronic lymphocytic leukemia.
Cyr MG, Mhibik M, Qi J, Peng H, Chang J, Gaglione EM, Eik D, Herrick J, Venables T, Novick SJ, Courouble VV, Griffin PR, Wiestner A, Rader C. Cyr MG, et al. Among authors: gaglione em. J Immunother Cancer. 2022 Nov;10(11):e004850. doi: 10.1136/jitc-2022-004850. J Immunother Cancer. 2022. PMID: 36442911 Free PMC article.
NRX-0492 degrades wild-type and C481 mutant BTK and demonstrates in vivo activity in CLL patient-derived xenografts.
Zhang D, Harris HM, Chen J, Judy J, James G, Kelly A, McIntosh J, Tenn-McClellan A, Ambing E, Tan YS, Lu H, Gajewski S, Clifton MC, Yung S, Robbins DW, Pirooznia M, Skånland SS, Gaglione E, Mhibik M, Underbayev C, Ahn IE, Sun C, Herman SEM, Noviski M, Wiestner A. Zhang D, et al. Among authors: gaglione e. Blood. 2023 Mar 30;141(13):1584-1596. doi: 10.1182/blood.2022016934. Blood. 2023. PMID: 36375120 Free PMC article.
Overcoming Acquired Epigenetic Resistance to BTK Inhibitors.
Shaffer AL 3rd, Phelan JD, Wang JQ, Huang D, Wright GW, Kasbekar M, Choi J, Young RM, Webster DE, Yang Y, Zhao H, Yu X, Xu W, Roulland S, Ceribelli M, Zhang X, Wilson KM, Chen L, McKnight C, Klumpp-Thomas C, Thomas CJ, Häupl B, Oellerich T, Rae Z, Kelly MC, Ahn IE, Sun C, Gaglione EM, Wilson WH, Wiestner A, Staudt LM. Shaffer AL 3rd, et al. Among authors: gaglione em. Blood Cancer Discov. 2021 Sep 14;2(6):630-647. doi: 10.1158/2643-3230.BCD-21-0063. eCollection 2021 Nov. Blood Cancer Discov. 2021. PMID: 34778802 Free PMC article.
Risk-adapted, ofatumumab-based chemoimmunotherapy and consolidation in treatment-naïve chronic lymphocytic leukemia: a phase 2 study.
Desai S, Mo C, Gaglione EM, Yuan CM, Stetler-Stevenson M, Tian X, Maric I, Wake L, Farooqui MZ, Drinkwater DC, Soto S, Valdez J, Hughes TE, Nierman P, Lotter J, Marti GE, Pleyer C, Sun C, Superata J, Nichols C, Herman SEM, Lindorfer MA, Taylor RP, Wiestner A, Ahn IE. Desai S, et al. Among authors: gaglione em. Leuk Lymphoma. 2021 Aug;62(8):1816-1827. doi: 10.1080/10428194.2021.1888379. Epub 2021 Mar 2. Leuk Lymphoma. 2021. PMID: 33653216 Free PMC article. Clinical Trial.
20 results